ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable HCC
By
ASCO 2022 Conference Coverage
FEATURING
Peter Galle
By
ASCO 2022 Conference Coverage
FEATURING
Peter Galle
73 views
July 9, 2022
Comments 0
Login to view comments.
Click here to Login
GI